CRANBURY, N.J.--(BUSINESS WIRE)--Two novel influenza vaccine candidates produced through an innovative technology have shown promising results in early testing, according to a presentation made by VaxInnate at the second “Influenza Vaccines for the World” conference. VaxInnate reported that vaccines fusing proteins or protein fragments from influenza virus with a protein from bacteria, and produced in a bacterial expression system, were able to deliver a highly efficacious response in mice.
